ID   MOLP-2/R
AC   CVCL_4V88
DR   cancercelllines; CVCL_4V88
DR   Wikidata; Q54906335
RX   DOI=10.1007/s10330-009-0051-5;
RX   PubMed=19756599;
CC   Population: Japanese.
CC   Characteristics: Produces IgD lambda.
CC   Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; LPAM; Alkeran).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2123 ! MOLP-2
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 11
//
RX   DOI=10.1007/s10330-009-0051-5;
RA   Xiao H., Xiao Q., Zhang K.-J., Zuo X.-L.;
RT   "A novel myeloma cell line identified for multidrug resistant study.";
RL   Chinese-German J. Clin. Oncol. 8:296-299(2009).
//
RX   PubMed=19756599; DOI=10.1007/s00277-009-0831-6;
RA   Xiao H., Xiao Q., Zhang K.-J., Zuo X.-L., Shrestha U.K.;
RT   "Reversal of multidrug resistance by curcumin through FA/BRCA pathway
RT   in multiple myeloma cell line MOLP-2/R.";
RL   Ann. Hematol. 89:399-404(2010).
//